/

Empresas

Fe

No verificado

Ferrer

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa

21/10/2025

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

Fuente

Editor

1.00

0

17/06/2025

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

Fuente

Editor

1.00

0

03/06/2025

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America

Fuente

Editor

1.00

0

28/04/2025

Mercado laboral

Biotecnología

Farmacéutica

Salud

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine

Fuente

Editor

1.00

0

31/03/2025

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

Fuente

Editor

1.00

0

20/02/2025

Multimedia

Responsabilidad Social Corporativa

Industria

Farmacéutica

Asociaciones/Profesionales

Medio Ambiente/Ecología

Transporte de mercancías

Biotecnología

Logística

Salud

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp

Fuente

Editor

1.00

0

30/01/2025

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

Fuente

Editor

1.00

0

20/11/2024

Análisis de Mercados

Industria

Ciencia

Medicina - Varios

Cardiología

Gestión empresarial

Biotecnología

Sanidad

Farmacéutica

Salud

Pulmonary Hypertension Awareness Month: Two European Studies Highlight the Urgency of Patients and Experts to Improve the Diagnosis and Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

Fuente

Editor

1.00

0

17/09/2024

Multimedia

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0